Design, Synthesis and Chemically Engineered Graphene Quantum Dot Applications: Contrast Agent for Mr Imaging and Targeted Therapeutics on Parkinson's Treatment

Abstract

Emerging clinically required cytotoxic and metal free contrast agent demand is increased in the society for patient safe MR imaging. This intend to chemically engineered the graphene quantum dot (GQD) with blue luminescence offer drug delivery guided metal free contrast agent for enhanced MR imaging across central nervous system (CNS) and to cure neurodegeneration in Parkinson’s disease. Simulation of MABM-GQD nanocomposite possess good electromagnetic scattering efficiency which leads to act as good contrast agent on bioimaging. α-synuclein (α-syn) aggregation has been accused as a critical step in development of Parkinson's disease. Hence narrow down the target by α-syn inhibition, which aims to design and chemically synthesize methyl N -allyl N -benzoylmethioninate (MABM) for functionally engineered the surface of GQD and targeted delivery to C57BL/6 mice brain. Spectroscopic and dynamic simulation studies confirmed the defibrillation through N-terminal amino acids interaction with MABM-GQD NPs makes non-toxic α-syn. Therefore, in vitro blood brain barrier crossing ability makes this drug functional to prevent neuronal loss in neuroblastoma cells. MR Imaging effortlessly evidenced improved image quality by the action of Chemical Exchange Saturation Transfer (CEST) contrast agent principle. Thus erebral blood flow (CBF) analysis using MRI illustrates this nanocomposite as dual mode vector for treatment of Parkinson’s and contrast agent.

Keywords: Graphene Quantum Dot, MR Imaging, CEST contrast agent, Parkinson's disease, α-synuclein, Neuroblastoma.